Can a smartwatch help control a common heart rhythm problem?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

7.2 Inclusion criteria In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Age ≥ 18 years old * ECG documented diagnosis of paroxysmal AF * Presence of symptomatic paroxysmal AF, defined as recurrent self-terminating AF (≥ 2 episodes in last 4 months) documented by typical symptoms, ECG or photoplethysmo-gram * Able and willing to sign informed consent. For SMART sub study only: \- Own a smartphone 7.3 Exclusion criteria A potential subject who meets any of the following criteria will be excluded from participation in this study: * A history of electrical cardioversion for persistent AF * History of AF episode \> 7 days * Previous or current chronic amiodaron use. * A history of pulmonary vein ablation * Taking part in another randomized trial * Reduced life-expectancy of \< 1 year * Presence of contra-indication for verapamil or metoprolol * Pregnant or breastfeeding women. Or women who are planning to become pregnant during the study period. * For substudy patients: already participating in an eHealth program Contraindications for verapamil or metoprolol: * Known hypersensitivity, intolerance or allergy to verapamil, metoprolol, or any excipi-ents. * Current use of verapamil, diltiazem, beta-blockers or digoxin, or \< 5 half-lives ago at the time of randomization. * Concomitant use of medications with absolute contraindications for verapamil or metoprolol (e.g., strong CYP3A4 inhibitors).\* * Resting heart rate \< 50 beats per minute at baseline. * Symptomatic hypotension (or systolic blood pressure \< 100 mmHg). * Second- or third-degree atrioventricular block. * Sick sinus syndrome or sinus node disease. * Wolff-Parkinson-White syndrome. * Severe heart failure (NYHA class III-IV or left ventricular ejection fraction \< 45%). * Clinically significant constipation requiring medical intervention. * Severe bronchial asthma or COPD with bronchial hyperreactivity. * Untreated pheochromocytoma (unless patient is concomitantly treated with an α-blocker). * Type 1 diabetes mellitus with frequent symptomatic hypoglycaemia where β-blocker use would pose unacceptable risk due to masking of symptoms. * Severe symptomatic peripheral arterial disease or disabling Raynaud's phenomenon. * Pacemaker therapy in place. An implanted loop recorder is not a contraindication. * Severe hepatic impairment (Child-Pugh class C). * Severe renal impairment (eGFR \< 30 ml/min/1.73m²). \*Patients using statins can be switched to an equivalent dose of rosuvastatin prior to ran-domization. Patients using oral anticoagulation need to be switched to apixaban or rivaroxa-ban.